ReviewJournal of nanobiotechnology2026
Nanomaterial-enabled smart contact lenses: bridging sensing, therapy, and theranostics for next-generation ocular healthcare.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smart contact lenses (CLs) are emerging as multifunctional biomedical platforms that merge vision correction with advanced diagnostic and therapeutic capabilities. By integrating nanomaterials with tailored optical, electronic, and structural properties into soft hydrogel matrices, CLs can continuously interface with tear fluid, enabling real-time access to a rich spectrum of ocular and systemic biomarkers. This review highlights the functional roles of nanomaterials in enabling electrochemical, plasmonic, and SERS-based diagnostics, as well as controlled release, photothermal, and antimicrobial therapies. We also discuss the emergence of theranostic CLs that couple real-time on-eye sensing with on-demand intervention, positioning them as prototypes of closed-loop ocular healthcare systems. Emphasis is placed on material design, functional integration, and clinical translation challenges, showing how nanotechnology is redefining CLs as next-generation, patient-tailored biomedical devices. The translational gap between proof-of-concept demonstrations and clinical practice is also evaluated, identifying key unresolved challenges in sensor validation, long-term biocompatibility, power management, and regulatory approval, and proposing a priority research agenda for the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.